Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study-Reference-Cited by-同舟云学术

Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study

Published:2006-11 Issue:17 Volume:42 Page:2968-2975
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Geisler J.,Lønning P.E.,Krag L.E.,Løkkevik E.,Risberg T.,Hagen A.I.,Schlichting E.,Lien E.A.,Øfjord E.S.,Eide G.E.,Polli A.,di Salle E.,Paolini J.

Publisher

Elsevier BV

Reference36 articles.

1. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer;Howell;Lancet,2005

2. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer;Goss;N Engl J Med,2003

3. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer;Coombes;N Engl J Med,2004

4. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial;Boccardo;J Clin Oncol,2005

5. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial;Jakesz;Lancet,2005

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes in LDL-cholesterol levels following aromatase inhibitor treatment in early postmenopausal breast cancer;European Journal of Epidemiology;2025-05-21

2. Secondary osteoporosis;Reference Module in Biomedical Sciences;2024

3. Clinical tools and counseling considerations for breast cancer risk assessment and evaluation for hereditary cancer risk;Best Practice & Research Clinical Obstetrics & Gynaecology;2022-06

4. Bone recurrence in early breast cancer patients: The paradox of aromatase inhibitors induced bone resorption;Breast Disease;2021-09-30

5. Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management;Frontiers in Endocrinology;2021-07-27